5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy

Published:2013 Issue:4 Volume:59 Page:273-279
ISSN:1421-9794
Container-title:Chemotherapy
language:en
Short-container-title:Chemotherapy

Author:

Lee Min Geun,Lee Sang Hyub,Lee Seung June,Lee Yoon Suk,Hwang Jin-Hyeok,Ryu Ji Kon,Kim Yong-Tae,Kim Dong Uk,Woo Sang Myung

Publisher

S. Karger AG

Subject

Infectious Diseases,Pharmacology (medical),Drug Discovery,Pharmacology,Oncology,General Medicine

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspectives on chemotherapy-induced toxicities in pancreatic cancer;Current Cancer Reports;2024-02-20

2. Clinical practice guidelines for interventional treatment of pancreatic cancer;Recent Advances in Nanocarriers for Pancreatic Cancer Therapy;2024

3. Dose evaluations of organs at risk and predictions of gastrointestinal toxicity after re-irradiation with stereotactic body radiation therapy for pancreatic cancer by deformable image registration;Frontiers in Oncology;2023-01-30

4. Drimia calcarata Bulb Extracts Deactivate the PI3K Signalling Pathway in Cervical HPV-18 Positive HeLa Cells;Clinical Complementary Medicine and Pharmacology;2022-12

5. Transcription factor p8 regulates autophagy in response to disulfiram via PI3K/mTOR/p70S6K signaling pathway in pancreatic cancer cells;Human Cell;2022-06-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP